Skip to content

Application of sub-anesthesia dose of esketamine in painless fiberoptic bronchoscopy with spontaneous breathing preservation

Application of sub-anesthesia dose of esketamine in painless fiberoptic bronchoscopy with spontaneous breathing preservation

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400093000
Enrollment
Unknown
Registered
2024-11-27
Start date
2024-12-01
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disease of respiratory system

Interventions

Control group :equal volume of physiological saline
esketamine group:intravenous infusion of 0.2 mg/kg esketamine

Sponsors

Jiangmen Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) The American Society of Anesthesiologists classifies it as Grade I-II; (2) Those who plan to undergo fiberoptic bronchoscopy under general anesthesia without intubation; (3) There are clear indications for painless fiberoptic bronchoscopy examination; (4) Those who voluntarily participate in the research and sign the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Preoperative oxygen inhalation with blood oxygen saturation less than 90%; (2) The patient has a history of depression or taking antidepressants; (3) Patients with neurological and psychiatric disorders or a history of drug abuse; (4) The patient's cooperation is poor and they are unable to cooperate with the scale evaluation; (5) After examination, the patient has abnormal liver and kidney function; (6) The patient has a history of thyroid dysfunction; (7) Patients who experience serious adverse reactions during bronchoscopy examination; (8) Severe hypertension, intraocular pressure, or intracranial pressure, with severe cardiovascular disease; (9) Individuals who are allergic to the drugs used in the research protocol.

Design outcomes

Primary

MeasureTime frame
Ramsay Sedation Scale, RSS;

Secondary

MeasureTime frame
mean arterial pressure, MAP;heart rate, HR;arterial oxygen saturation, SpO2;Quality of Recovery-15, QoR-15;

Countries

China

Contacts

Public ContactShijie Deng

Jiangmen Central Hospital

530666716@qq.com+86 186 7502 2201

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026